SCHEMBL826288

SCHEMBL826288

C=CCCCCCCCCC(=O)CCCCC(=O)O

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.87
ABCC4 O15439 1/20 0.87
KMT2A Q03164 2/20 0.54
LMNA P02545 3/20 0.52
TSHR P16473 1/20 0.52
NFKB1 P19838 1/20 0.52
PMP22 Q01453 1/20 0.52
ALDH1A1 P00352 2/20 0.52
TERT O14746 3/20 0.48
PTPN1 P18031 3/20 0.48
PPARG P37231 3/20 0.48
PPARD Q03181 3/20 0.48
PPARA Q07869 3/20 0.48
BLM P54132 2/20 0.48
HSD17B10 Q99714 2/20 0.48
FABP4 P15090 2/20 0.48
F7 P08709 2/20 0.48
F3 P13726 2/20 0.48
GMNN O75496 1/20 0.48
USP2 O75604 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4422106 1.00 MAPT (0.87) MAPTABCC4KMT2ALMNATSHR
SCHEMBL3136737 1.00 MAPT (0.87) MAPTABCC4KMT2ALMNATSHR
SCHEMBL13346202 1.00 MAPT (0.87) MAPTABCC4KMT2ALMNATSHR
SCHEMBL11247321 1.00 MAPT (0.87) MAPTABCC4KMT2ALMNATSHR
SCHEMBL3133627 0.96 MAPT (0.79) MAPTABCC4KMT2ALMNATSHR
SCHEMBL823728 0.93 MAPT (0.75) MAPTABCC4KMT2ALMNATSHR
Undecylenic Acid SCHEMBL17827 0.93 MAPT (1.00) MAPTABCC4KMT2ALMNATSHR
SCHEMBL465896 0.93 MAPT (1.00) MAPTABCC4KMT2ALMNATSHR
Undecylenic Acid SCHEMBL4464618 0.93 MAPT (1.00) MAPTABCC4KMT2ALMNATSHR
Undecylenic Acid SCHEMBL5974072 0.93 MAPT (1.00) MAPTABCC4KMT2ALMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541406-B2 Phase change inks containing curable isocyanate-derived compounds XEROX CORPORATION (US) 2009-06-02 US claimed
US-20070123642-A1 Phase change inks containing curable isocyanate-derived compounds XEROX CORPORATION 2007-05-31 US claimed
US-20070120909-A1 Phase change inks containing curable isocyanate-derived compounds and phase change inducing components XEROX CORPORATION 2007-05-31 US claimed
US-8142720-B2 Molecules suitable for binding to a metal layer for covalently immobilizing biomolecules IMEC (BE) 2012-03-27 US disclosed
US-20110316926-A1 Organic Phase Change Carriers Containing Nanoparticles, Phase Change Inks Including Same and Methods for Making Same XEROX CORPORATION (US) 2011-12-29 US disclosed
US-20100284860-A1 MOLECULES SUITABLE FOR BINDING TO A METAL LAYER FOR COVALENTLY IMMOBILIZING BIOMOLECULES IMEC (BE) 2010-11-11 US disclosed
US-7770437-B2 Thiol or disulfide molecules having poly(ethylene oxide) groups for use in a self assembled monolayer bound to a metal layer for covalently immobilizing biomolecules in a biosensor IMEC (BE) 2010-08-10 US disclosed
US-20100116424-A1 ORGANIC PHASE CHANGE CARRIERS CONTAINING NANOPARTICLES, PHASE CHANGE INKS INCLUDING SAME AND METHODS FOR MAKING SAME XEROX CORPORATION (US) 2010-05-13 US disclosed
US-7714087-B2 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS, INC. (JP) 2010-05-11 US disclosed
US-7714087-B2 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS, INC. (JP) 2010-05-11 US disclosed
US-7699922-B2 Organic phase change carriers containing nanoparticles, phase change inks including same and methods for making same XEROX CORPORATION (US) 2010-04-20 US disclosed
US-7393907-B2 Polar group-containing olefin copolymer, process for preparing the same, thermoplastic resin composition containing the copolymer, and uses thereof MITSUI CHEMICALS, INC. (JP) 2008-07-01 US disclosed
US-20070283846-A1 Organic Phase Change Carriers Containing Nanoparticles, Phase Change Inks Including Same and Methods for Making Same XEROX CORPORATION (US) 2007-12-13 US disclosed
US-20070272003-A1 2-(2-{2-[2-(2-{2-[2-(11-mercaptoyldisulfanyl-undecyloxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy} acetic acid pentafluorophenyl ester; poly(ethylene oxide) groups resist nonspecific adsorption and enhance the specific affinity interactions IMEC (BE) 2007-11-29 US disclosed
EP-1798250-A2 Molecules suitable for binding to a metal layer for covalently immobilizing biomolecules INTERUNIVERSITAIR MICROELEKTRONICA CENTRUM vzw (IMEC) (BE) 2007-06-20 EP disclosed
US-20070123642-A1 Phase change inks containing curable isocyanate-derived compounds XEROX CORPORATION 2007-05-31 US disclosed
US-20070123641-A1 Phase change inks containing compounds derived from isocyanate, unsaturated alcohol, and polyol XEROX CORPORATION 2007-05-31 US disclosed
US-20070120909-A1 Phase change inks containing curable isocyanate-derived compounds and phase change inducing components XEROX CORPORATION 2007-05-31 US disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100284860-A1 MOLECULES SUITABLE FOR BINDING TO A METAL LAYER FOR COVALENTLY IMMOBILIZING BIOMOLECULES EBPL, SPR, MB MAPT 4448/4885ABCC4 4218/4885KMT2A 3264/4885
US-20070272003-A1 2-(2-{2-[2-(2-{2-[2-(11-mercaptoyldisulfanyl-undecyloxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy} acetic acid pentafluorophenyl ester; poly(ethylene oxide) groups resist nonspecific adsorption and enhance the specific affinity interactions EBPL, AEBP2, NAPA MAPT 4752/4885ABCC4 4535/4885KMT2A 3326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.